Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 8/20 | 0.41 |
| ▸ | EDNRA | P25101 | 2/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 8/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8552487 | 0.91 | EDNRB (0.44) | EDNRBEDNRA | |
| SCHEMBL8551818 | 0.89 | EDNRB (0.41) | EDNRBEDNRAKDM4EALDH1A1 | |
| SCHEMBL8549138 | 0.89 | EDNRB (0.46) | EDNRBEDNRAPLA2G2A | |
| SCHEMBL8551802 | 0.84 | EDNRB (0.39) | EDNRBEDNRAALDH1A1 | |
| SCHEMBL8549137 | 0.83 | EDNRB (0.58) | EDNRBEDNRAPLA2G2A | |
| SCHEMBL8547858 | 0.83 | EDNRB (0.43) | EDNRBEDNRA | |
| SCHEMBL8549390 | 0.83 | EDNRB (0.48) | EDNRBEDNRA | |
| SCHEMBL8550420 | 0.83 | EDNRB (0.61) | EDNRBEDNRAHPGD | |
| SCHEMBL8552678 | 0.82 | EDNRB (0.43) | EDNRBEDNRAPLA2G2A | |
| SCHEMBL8552610 | 0.81 | EDNRB (0.46) | EDNRBEDNRAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0863898-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997019077-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-05-29 | — | — | WO | disclosed |